Core Insights - The Ministry of Industry and Information Technology and the National Medical Products Administration have announced the second batch of companies selected for the "Innovative Task of Biomedical Materials" initiative, with 14 companies from Beijing, including AoJing Medical Technology Co., Ltd. recognized for its "degradable semi-hydrated calcium sulfate" medical material [1][7] Company Overview - AoJing Medical is focused on the research, development, production, and sales of implantable medical devices for tissue regeneration and repair. The company pioneered the development of mineralized collagen biomimetic bone materials that closely resemble natural human bone tissue in composition and structure, achieving clinical transformation and industrialization [2][4] - The mineralized collagen biomimetic bone material consists of collagen and mineral components, such as hydroxyapatite, offering excellent biocompatibility and mechanical properties. It has been used in over one million clinical cases, demonstrating significant effectiveness in bone defect repair and regeneration [2][4] Industry Development - The Daxing Biomedical Industry Base is actively promoting the construction of specialized industrial parks, focusing on key technology research and development in high polymer materials, metal materials, and inorganic non-metallic materials [4][11] - The "Innovative Task of Biomedical Materials" initiative aims to address critical challenges in the industry, with selected companies receiving support in financing and regulatory reviews to accelerate technology transfer and application [11] - The Daxing Biomedical Industry Base has been officially named the "Zhongguancun (Daxing) Biomedical Materials Industrial Park," emphasizing its role in integrating medical and engineering sectors and fostering innovation in biomedical materials and medical devices [9][11]

Core Insights - The project "Key New Technologies and Applications of Highly Active Bone Repair Materials," led by Huazhong University of Science and Technology and deeply involving AoJing Medical (688613.SH), has won the first prize of the China Biomaterials Society Science and Technology Award due to its originality, industry innovation, and significant clinical transformation value [1][4]. Group 1: Company Achievements - AoJing Medical has developed a series of Class III medical device products based on extensive research of natural bone tissue, utilizing a biomimetic mineralization technique that simulates the mineralization process of bone tissue in vivo [3][4]. - Since its approval for market entry in 2011, AoJing Medical's products have been clinically applied in millions of cases, significantly improving the quality of life for many patients and generating notable social and economic benefits [4]. Group 2: Technological Recognition - The award received in 2025 is a recognition of the technological leadership of AoJing Medical in the field of highly active bone repair materials, affirming the originality and international leading status of its patented technologies such as in vitro biomimetic mineralization [4]. - The project aligns with the company's core technology system, further validating the innovative value of its research and development efforts over the years [4].

Core Viewpoint - The article provides a comprehensive overview of the Chinese biomedical materials industry, highlighting key listed companies, their business segments, revenue projections, and strategic planning for future growth. Group 1: Overview of Listed Companies - The A-share listed companies in the biomedical materials sector include Guocera Materials, Weigao Orthopedics, Haohai Biological Technology, Lepu Medical, Lanfang Medical, and Xinmai Medical [1] - The industry is characterized by a diverse range of companies focusing on various segments such as biocomposite materials, biopolymers, and biometals [2][3] Group 2: Revenue Projections - For 2024, key revenue figures for selected companies include: - Guocera Materials: 40.47 billion CNY from dental ceramics and biomedical materials [4] - Weigao Orthopedics: 14.51 billion CNY from orthopedic implants [10] - Lepu Medical: 61.03 billion CNY from cardiovascular materials [5] - The overall revenue for the biomedical materials sector is projected to grow, driven by increasing demand for advanced medical solutions [11] Group 3: Business Layout and Performance - Companies like Aojing Medical, Weigao Orthopedics, and Dabo Medical derive nearly 100% of their revenue from biomedical materials, indicating a focused business strategy [9] - The production and sales rates for biomedical materials are generally below 100%, with companies like Aojing Medical and Weigao Orthopedics showing lower production efficiency [11] Group 4: Strategic Planning and Innovation - Leading companies are focusing on technological innovation, market expansion, and integration of the supply chain to maintain competitive advantages [13] - Companies such as Guocera Materials and Weigao Orthopedics are investing in R&D and international market penetration to enhance their product offerings and market share [14][15]

Core Viewpoint - The recent passing of 崔福斋, a key figure in 奥精医疗, is noted, but the company asserts that this will not affect its management stability or operational independence. However, the company is facing significant challenges due to a nationwide centralized procurement policy impacting its financial performance [6][9]. Company Overview - 奥精医疗, founded in 2004 by 崔福斋, is a leading enterprise in the field of artificial bone repair materials, focusing on the research, development, production, and sales of medical devices for tissue regeneration [8]. - The company achieved a market share of 13% in the artificial bone repair materials sector in 2020 [10]. Financial Performance - In 2024, 奥精医疗 is projected to experience a revenue decline of 9.03% and a net profit decrease of 123.35%, resulting in a loss of 12.66 million yuan [6][10]. - The primary reason for this decline is the implementation of centralized procurement for orthopedic artificial bones, which has led to a significant drop in product prices and increased operational costs [10][11]. Market Dynamics - The orthopedic bone repair materials market is currently dominated by allogeneic bone, which accounts for approximately two-thirds of the market. However, legal and ethical issues surrounding allogeneic bone may enhance the market share of artificial bone repair materials [10]. - The average price reduction for orthopedic medical consumables due to centralized procurement is reported to be 74%, which has adversely affected 奥精医疗's pricing and revenue [10]. Future Outlook - 奥精医疗 is expanding its business by acquiring HumanTech Dental in 2024, which will enhance its presence in the dental implant sector [11]. - The company is also increasing its sales personnel and marketing activities, which will lead to higher sales expenses and credit impairment losses [11].

Core Viewpoint - The passing of Cui Fuzhai, the founder and actual controller of AoJing Medical, is a significant event for the company, but it is stated that his death will not impact the company's operations or management stability [1][4]. Group 1: Company Background - AoJing Medical (688613.SH) is a leading enterprise in the biomaterials industry and a listed company on the Sci-Tech Innovation Board, founded by Cui Fuzhai in 2004 [1][5]. - The company specializes in the research, development, production, and sales of implantable medical devices aimed at tissue regeneration and repair [5]. - AoJing Medical developed the mineralized collagen biomimetic bone material in 2011, which closely resembles natural human bone tissue, achieving clinical transformation and industrialization [5]. Group 2: Contributions of Cui Fuzhai - Cui Fuzhai held multiple academic and professional roles, including professor and doctoral supervisor at Tsinghua University, and was recognized as a fellow by several prestigious engineering societies [3][4]. - His research focused on biomaterials science and engineering, particularly in the areas of natural mineralization mechanisms of bones and teeth, and the development of biomimetic materials [4]. - Under his leadership, AoJing Medical has launched a series of patented products, including mineralized collagen artificial bone powder and membranes, which have been widely used in clinical settings [4][5]. Group 3: Shareholding and Succession - As of the announcement date, Cui Fuzhai directly held 6.3348 million shares of AoJing Medical, accounting for 4.62% of the total share capital, and indirectly held 354,100 shares through a partnership [1]. - The shares held by Cui Fuzhai will be subject to inheritance procedures according to legal regulations, and the company will fulfill its information disclosure obligations as necessary [1].